Monitoring Disease Activity in Patients With Takayasu Arteritis With the OMERACT Takayasu Ultrasound Score (OTUS) (MOTUS)
6 mai 2026 mis à jour par: Tomelleri Alessandro, IRCCS San Raffaele
A Multicenter Prospective Observational Study on the Role of the OMERACT Takayasu Ultrasound Score (OTUS) in Monitoring Disease Activity in Patients With Takayasu Arteritis
This is a multicenter prospective observational study aimed at evaluating the role of an ultrasonographic score in monitoring disease activity in patients with Takayasu arteritis (TAK).
Patients with active disease, either at new diagnosis or during relapse, will undergo serial vascular US assessments during follow-up according to routine clinical practice at each participating centers.
For each patient, an OMERACT-derived US score (OTUS) will be calculated.
This score was developed and preliminarily validated in previous phases of a multistep project endorsed by OMERACT (Outcome Measures in Rheumatology), an international initiative focused on the development and validation of outcome measures in rheumatology.
The study hypothesis is that this score is sensitive to change over time and can be used to monitor disease activity and predict outcome in patients with TAK.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Description détaillée
This is an observational study.
The study concerns a diagnostic procedure (vascular US) that is part of normal clinical practice for patients with large-vessel vasculitis (LVV).
The decision to perform vascular US in patients with TAK will remain independent from the decision to enroll the patient in the study.
No investigational medicinal product or experimental device is involved.
The procedure under study is an ultrasonographic scoring system derived from vascular US examinations of selected arterial segments in patients with TAK.
Examinations will be performed according to standardized OMERACT protocols, including assessment of the common carotid, subclavian and axillary arteries, and the abdominal aorta.
For each patient, an OMERACT-derived OTUS score will be calculated at each assessment.
No comparator is mandated; however, clinical disease activity state and results from other imaging modalities (FDG-PET, MRA, CTA), when available as part of routine clinical care, will be collected for exploratory analyses.
Study participation will last 24 months, during which patients will undergo serial US examinations at predefined follow-up visits as part of routine clinical monitoring.
Vascular US is a non-invasive, radiation-free and contrast-free technique, already employed in standard clinical care and used here exclusively for observational purposes.
Type d'étude
Observationnel
Inscription (Estimé)
100
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
The study population will consist of patients with TAK and active disease, either newly diagnosed or experiencing a relapse. Active disease is defined as the presence of clinical signs and/or symptoms attributable to TAK, with or without elevation of inflammatory markers (ESR, CRP), and/or imaging evidence of active vasculitis (excluding US findings used in OTUS scoring).
Patients of any gender, aged ≥18 years, will be eligible.
La description
Inclusion Criteria:
- Age ≥18 years
- Male and female
- Diagnosis of TAK according to the 1990 ACR and/or 2022 ACR/EULAR classification criteria
Active disease, defined as the presence of at least two of the following three domains:
- Clinical domain: new onset or worsening of clinical signs and/or symptoms attributable to TAK;
- Laboratory domain: elevation of inflammatory markers, defined as ESR and/or CRP above the upper limit of normal according to local laboratory standards, not attributable to causes other than TAK;
- Imaging domain: imaging evidence of active vasculitis on modalities other than ultrasound, including FDG-PET, magnetic resonance angiography (MRA), or computed tomography angiography (CTA).
- Ability to undergo serial vascular ultrasound assessments during follow-up
- Provision of signed informed consent
Exclusion Criteria:
- Inability or contraindication to undergo vascular US
- Severe comorbidities limiting participation or follow-up
- Concomitant conditions that may confound ultrasound findings (e.g., significant atherosclerosis requiring intervention, complete occlusion of one of the arterial segments under investigation)
- Diagnosis of another rheumatologic disease
- Refusal or inability to provide informed consent
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in OTUS between active disease and remission in patients with Takayasu arteritis
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24. For the primary endpoint only baseline → first remission visit will be analyzed.
|
Change in OTUS from baseline (active disease) to the first visit at which clinical remission is achieved, as determined by the treating physician (blinded to ultrasound results).
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24. For the primary endpoint only baseline → first remission visit will be analyzed.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate the agreement between OTUS-based activity assessment and NIH disease activity score
Délai: Baseline, month 1, month 3, month 6, month 12, month 18, month 24
|
Cohen's kappa coefficient measuring agreement between OTUS-based disease activity classification and the National Institutes of Health (NIH) disease activity score for Takayasu arteritis (range 0-4, with higher scores indicating more active disease).
|
Baseline, month 1, month 3, month 6, month 12, month 18, month 24
|
|
Hazard ratio for time to relapse per unit increase in baseline OTUS score
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Time to disease relapse (months), defined as recurrence of clinical signs and/or symptoms attributable to TAK with or without elevation of inflammatory markers, as judged by the treating physician.
The hazard ratio per unit increase in baseline OTUS score will be estimated using Cox proportional-hazards regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Hazard ratio for time to vascular damage progression per unit increase in baseline OTUS score
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Time to vascular damage progression (months), defined as new or worsening stenosis, occlusion, or aneurysm detected on CTA, MRA, or vascular US compared to baseline.
The hazard ratio per unit increase in baseline OTUS score will be estimated using Cox proportional-hazards regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Odds ratio for successful glucocorticoid discontinuation per unit increase in baseline OTUS score
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Proportion of patients achieving successful glucocorticoid discontinuation, defined as complete GC tapering without relapse for at least 3 consecutive months.
The odds ratio per unit increase in baseline OTUS score will be estimated using logistic regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Hazard ratio for time to relapse per unit increase in OTUS change from baseline to month 3
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Time to disease relapse (months), defined as recurrence of clinical signs and/or symptoms attributable to TAK with or without elevation of inflammatory markers, as judged by the treating physician.
The hazard ratio per unit increase in OTUS change from baseline to month 3 (ΔOTUS) will be estimated using Cox proportional-hazards regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Hazard ratio for time to vascular damage progression per unit increase in OTUS change from baseline to month 3
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Time to vascular damage progression (months), defined as new or worsening stenosis, occlusion, or aneurysm detected on CTA, MRA, or vascular US compared to baseline.
The hazard ratio per unit increase in OTUS change from baseline to month 3 (ΔOTUS) will be estimated using Cox proportional-hazards regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Odds ratio for successful glucocorticoid discontinuation per unit increase in OTUS change from baseline to month 3
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Proportion of patients achieving successful glucocorticoid discontinuation, defined as complete GC tapering without relapse for at least 3 consecutive months.
The odds ratio per unit increase in OTUS change from baseline to month 3 (ΔOTUS) will be estimated using logistic regression.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
To assess the diagnostic ability of OTUS to detect clinical relapse during follow-up.
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Diagnostic performance of OTUS for relapse detection
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Absolute OTUS score in treatment responders vs non-responders
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Absolute OTUS score at each visit compared between clinical responders and non-responders to treatment, defined by physician global assessment.
Difference between groups will be assessed using Mann-Whitney U test, with effect size estimation.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
OTUS change from baseline (ΔOTUS) in treatment responders vs non-responders
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Change in OTUS score from baseline to each follow-up visit (ΔOTUS) compared between clinical responders and non-responders to treatment, defined by physician global assessment.
Difference between groups will be assessed using Mann-Whitney U test, with effect size estimation.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Correlation between OTUS changes and clinical/laboratory markers of disease activity in Takayasu arteritis
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Correlation between OTUS variation and: (i) ESR/CRP; (ii) clinical disease activity, as assessed by the Physician Global Assessment (PGA) of disease activity (0-10 visual analogue scale) and the National Institutes of Health (NIH) disease activity score for Takayasu arteritis.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Agreement between OTUS-based disease activity classification and Physician Global Assessment (PGA) in Takayasu arteritis
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Cohen's kappa coefficient measuring agreement between OTUS-based disease activity classification and Physician Global Assessment (PGA) of disease activity, assessed on a 0-10 visual analogue scale.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Reference values for arterial wall thickness measured by vascular ultrasound in assessed arterial segments
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Arterial wall thickness (mm) measured by standardized vascular ultrasound in the bilateral common carotid, subclavian and axillary arteries, and abdominal aorta.
Descriptive statistics will be used to define reference values and proposed normality cut-offs.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Change in OTUS score over time stratified by treatment class
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Change in OTUS score (continuous, expressed as ΔOTUS from baseline) over 24 months, compared across therapeutic classes (e.g., glucocorticoids alone, conventional immunosuppressants, biologics).
Differences between treatment groups will be analyzed using linear mixed-effects models.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
Proportion of patients with changes in ultrasound lesion characteristics over time stratified by treatment class
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Proportion of patients (%) showing new, resolved, or persistent elementary ultrasound lesions (macaroni sign, stenosis, occlusion) as defined by OMERACT criteria, compared across therapeutic classes.
Differences between treatment groups will be described using proportions and compared using chi-square or Fisher's exact test as appropriate.
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
|
To compare OTUS findings with FDG-PET, MRA and/or CTA obtained as part of routine clinical practice.
Délai: US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Concordance between OTUS and PET/MRA/CTA findings, both qualitative and quantitative (when available).
|
US performed at baseline, month 1, month 3, month 6, month 12, month 18, month 24.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 juillet 2026
Achèvement primaire (Estimé)
31 décembre 2032
Achèvement de l'étude (Estimé)
31 décembre 2032
Dates d'inscription aux études
Première soumission
23 avril 2026
Première soumission répondant aux critères de contrôle qualité
30 avril 2026
Première publication (Réel)
6 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
11 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
6 mai 2026
Dernière vérification
1 mai 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TAK-MOTUS
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .